IRCT20151227025726N28招募中2 期
Evaluating the efficacy and safety of remdesivir in severe COVID-19 in hospitalized patients
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 100 years（—）
- 性别
- All
入选标准
- •Patients above 18 years old
- •Confirmed COVID-19 (Corona Virus Disease-19) with RT-PCR (Real-Time Polymerase Chain Reaction)
- •Lung CT scan confirming lung involvement
- •Hospitalized with SaO2/SPO2=94% in room air or having Pa02/Fi02 <300mgHg
- •Becoming symptomatic within the past two weeks
排除标准
- •Severe liver disease (Child Pugh score = C, AST>10 times upper limit)
- •Breastfeeding
- •Sever renal failure ( estimated glomerular filtration rate =30 mL/min/1.73 m2) or receiving dialysis
- •Drug interactions (Methimazole, chloroquine, hydroxychloroquine)
研究者
相似试验
招募中
3 期
Assessment of utility of Remdesivir in Patients with Acute Kidney Injury or Cronic Kidney Disease in admitted COVID-19 patientsCondition 1: COVID-19. Condition 2: Acute Kidney Injury. Condition 3: Chronic Kidney Disease.Coronavirus infection, unspecifiedAcute kidney failureChronic kidney disease (CKD)B34.2IRCT20210709051824N1Men's Health and Reproductive Health Research Center(MHRHRC)100
招募中
3 期
Efficacy of Remdesivir in Comparison with Interferon Beta-1 a and Remdesivir in the Treatment of Covid 19IRCT20200721048159N4Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences100
已完成
2 期
Effect of remdesivir in COVID-19COVID-19.Corona virus infection, unspecifiedU07.1IRCT20200404046937N5Ahvaz University of Medical Sciences50
尚未招募
不适用
A retrospective analysis to study the Effectiveness and Safety profile of Remdesivir therapy in patients who diagnosed with COVID-19CTRI/2021/01/030433Dr Vishal Shanbhag
尚未招募
不适用
safety of remdesivir use in patients with impaired kidney function and covid 19 infectioCTRI/2020/12/030046DrMaulin Shah